Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer | Zendy

Yago Nieto | Zendy; José Manuel Aramendía | Zendy; J. Espinós | Zendy; Susana De La Cruz | Zendy; Óscar Fernández-Hidalgo | Zendy; Marta Santisteban | Zendy; L. Arbea | Zendy; Javier Aristu | Zendy; Rafael Martı́nez-Monge | Zendy; Marta Moreno | Zendy; Luis Pina | Zendy; Josu Sola | Zendy; G Zornoza | Zendy; Fernando Martínez Regueira | Zendy

Open Access

Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

Author(s) -

Yago Nieto,

José Manuel Aramendía,

J. Espinós,

Susana De La Cruz,

Óscar Fernández-Hidalgo,

Marta Santisteban,

L. Arbea,

Javier Aristu,

Rafael Martı́nez-Monge,

Marta Moreno,

Luis Pina,

Josu Sola,

G Zornoza,

Fernando Martínez Regueira

Publication year - 2009

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-009-1049-y

Subject(s) - capecitabine , medicine , docetaxel , epirubicin , breast cancer , metastatic breast cancer , cyclophosphamide , oncology , chemotherapy , gastroenterology , urology , cancer , surgery , colorectal cancer

Capecitabine is effective against metastatic breast cancer (MBC). We hypothesized that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and docetaxel/capecitabine would be active and tolerable in the adjuvant/neoadjuvant setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research